Thrive Genetics (Unchained Health)

We identify the genetic & behavioral predisposition of addiction in humanity, leveraging our ai-assisted platform that unlocks limitless possibilities for human well-being.

Company Overview

Thrive Genetics (formally Unchained Health, Inc.) The driving force behind building Thrive Genetics started right “at home” from personal experience and family related trauma. Co-Founder James Piacentino came from a family with an alcoholic father and always had the burning question related to this painful family experience; “Is addiction truly in our genes?” And if so, “can addiction be passed down generation to generation?” Closing the loop on this lifelong uncertainty, Unchained Health has a driving passion for helping others understand their risks. When the Co-Founders met leading Genetics and Psychology Ph. D, Dr. Danielle Dick, with her 20+ years of research on risk prediction for addiction, the idea for the company came to fruition. The team is now focused on first to market commercialization of genetic predisposition management product /solution proving that addiction is both genetic and behavioral. Unchained Health Inc. is now on deferral backed by law firm Perkins Coie. The company is working closely in the clinical field w/ support and leadership from globally recognized celebrity clinician Leah Randi, (Executive Advisor).

The company is currently run by the founders in a pre-market capacity and is set up as an incorporation. Mr. Piacentino and Dr. Dick are equal co-founders with an equity stake also owned by Leah Randi, Executive Advisor. Although the company is early stage, the work that has gone into this entity has been over 20 years of service in scientific and genetic research (DD), 20 years in the software, e-commerce technology sector, venture capital (JP) that will uniquely position this product and service line for mass appeal and success.

The PRODUCT / SaaS Service will consist of two distinctive features (Part 1 & Part 2, see figure) that will allow us to deliver value to customers quantitatively and qualitatively. We will deliver this value through a genetic testing kit that identifies genetic risk for addiction and combines that information with an environmental/behavioral behavior assessment to give personalized risk estimates (Part 1 Quantitative Gene + Environment Assessment).  This will be a SaaS model for B2B with a fee for use including product usage costs.

We will DIFFERENTIATE our offering from the entire market by then offering a service that provides curated and recommended products and services (affiliated marketing programs and interactive journey) to take a proactive approach to your health (Part 2 Qualitative “Life Plan” below). We will help the clinician and YOU manage your data results and maximize your ability. Repeat purchasing will come in the form of Part 2, noted below in the ongoing products the customer will buy via the affiliated marketing programs we will have. The B2B2C Addiction Clinic model will drive volume; the app (Part 2) will be designed to drive long-term customer value, and human development.

Market, Customer, and Competition Focus Areas - The market has several areas of opportunity.

 

Primary / Secondary Economic Buyer: Young professionals + Parents, student athletes who want to start a conversation about risk with their teenagers, responsible use of substances, and the need to attend to their mental health. We will also use social media to spread information about our product to groups and influencers in the substance use space (e.g., the Sober Curious movement).

Competitive Landscape: First mover advantage in this specific addiction space:
The exponential growth in DTC genetic testing means there is a proliferation of DTC genetic companies. Listed below are

illustrative examples, with pricing information and an overview of services offered:

Milestone Achievements in 9 months:

One of the advantages of our product are relatively low startup costs associated with the initial build-out and launch of the product. Part 1 (noted above) will involve the initial development of the interactive platform that will provide personalized risk estimates and evidence-based resources targeting the DTC and B2B Markets. Accordingly, the primary costs are associated with website development and personnel to develop further the content to be delivered. In addition, we must set up contracts with DNAGenotek to provide DNA collection kits, order fulfillment, purchase inventory, and Gencove to provide genotyping services. We have established arrangements in place. We must also establish systems for tracking orders and securely storing data on the cloud which is also arranged. The Artificial Intelligence platform would be executed in Part 2 funding for the development platform that will provide a proactive life plan for each customer.

Pre Seed and Seed Funding: We are seeking funding from various channels for the Phase 1 website buildout and product procurement (minimum order of DNA kits/genotyping costs). We are seeking Seed Investment of $500K to lock in the MVP for Q1. Funding, localized state grants angel funding from friends and family who are part of the addiction recovery movement and accredited investors that invest in early-stage and seed-stage companies seeking $5.5M to secure runway, invest in the markets and pivot if needed based on early data. Further, we will seek institutional and corporate venture capital investors downstream and build upon the platform concept leveraging AI to create interest amongst investors as the data of our platform increases in volume and value. In closing, our goal is to work with a long tern strategic investment team that shares our values and has skin in the game.